Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 117Rituximab 115fludarabine phosphate 79Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 55Whole-Body Irradiation 52Filgrastim 49Tacrolimus 43Cyclosporine 43Radiotherapy 41Busulfan 41Antilymphocyte Serum 38Etoposide 36Melphalan 34Lenalidomide 31Methotrexate 25fludarabine 23Cord Blood Stem Cell Transplantation 22Bortezomib 20Flow Cytometry 19Cytarabine 19Methylprednisolone 18Bendamustine Hydrochloride 18obinutuzumab 17Prednisone 15Granulocyte Colony-Stimulating Factor 15Carmustine 15sargramostim 14orelabrutinib 14Therapeutics 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell, Marginal Zone × ALX148 × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡